Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.88 USD
+0.20 (1.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ROIV 11.88 +0.20(1.71%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Stock Market News for Nov 14, 2023
Other News for ROIV
H.C. Wainwright Announces 26th Annual Global Investment Conference, September 9-11, 2024. Event Features Leading Industry Keynote Addresses by Vivek Ramaswamy, Michael Saylor; Bitcoin Panel Moderated by Anthony Scaramucci.
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright
Wall Street Analysts Are Bullish on Top Healthcare Picks